These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34649965)

  • 1. Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.
    Rotea-Salvo S; Martínez-Pradeda A; Fernández-Oliveira C; Giménez-Arufe V; Balboa-Barreiro V; Margusino-Framiñán L; Mena-De-Cea Á; Vázquez-Rodríguez P; Castro-Iglesias Á; López-Calvo S; Martín-Herranz I; Míguez-Rey E; Cid-Silva P
    Eur J Hosp Pharm; 2023 Jul; 30(4):221-226. PubMed ID: 34649965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
    Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
    BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens.
    Priest J; Germain G; Laliberté F; Duh MS; Mahendran M; Fakih I; Oglesby A
    Infect Dis Ther; 2023 Aug; 12(8):2117-2133. PubMed ID: 37552426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
    Devred I; Kayembe K; Valin N; Rougier H; Shinga BW; Lambert-Niclot S; Chiarabini T; Meyohas MC; Lacombe K
    BMC Infect Dis; 2023 Sep; 23(1):578. PubMed ID: 37667182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid profile changes associated with antiretroviral therapies in a real-world cohort.
    Rotea-Salvo S; Giménez-Arufe V; Martínez-Pradeda A; Fernández-Oliveira C; Mena-de-Cea Á; Margusino-Framiñán L; Martín-Herranz I; Cid-Silva P
    Farm Hosp; 2023; 47(5):T210-T217. PubMed ID: 37673703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid profile changes associated with antiretroviral therapies in a real-world cohort.
    Rotea-Salvo S; Giménez-Arufe V; Martínez-Pradeda A; Fernández-Oliveira C; Mena-de-Cea Á; Margusino-Framiñán L; Martín-Herranz I; Cid-Silva P
    Farm Hosp; 2023; 47(5):210-217. PubMed ID: 37349200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016.
    Perez Valero I; Cabello A; Ryan P; De La Fuente-Moral S; Santos I; Vivancos MJ; Gonzalez A; Gorgolas M; Cuevas G; Diaz De Santiago A; Cano J; Rua G; Yllescas M; González García JJ
    Open Forum Infect Dis; 2020 Dec; 7(12):ofaa482. PubMed ID: 33335931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine.
    Rogatto F; Bouee S; Jeanbat V; Piontkowsky D; Aragao F; Bosse M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19779. PubMed ID: 25397523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.
    Colson A; Chastek B; Gruber J; Majethia S; Zachry W; Mezzio D; Rock M; Anderson A; Cohen JP
    J Manag Care Spec Pharm; 2024 Aug; 30(8):817-824. PubMed ID: 39088337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF
    Zhang F; Wu H; Cai W; Ma P; Zhao Q; Wei H; Lu H; Wang H; He S; Chen Z; Chen Y; Wang M; Wan W; Fu H; Qin H
    Lancet Reg Health West Pac; 2024 Aug; 49():101143. PubMed ID: 39092318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
    Suárez-García I; Alejos B; Hernando V; Viñuela L; Vera García M; Rial-Crestelo D; Pérez Elías MJ; Albendín Iglesias H; Peraire J; Tiraboschi J; Díaz A; Moreno S; Jarrín I;
    J Antimicrob Chemother; 2023 Jun; 78(6):1423-1432. PubMed ID: 37099559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
    Evitt LA; Nanji S; Grove RA; Okoli C; van Wyk J; Snedecor SJ
    AIDS Res Ther; 2023 Mar; 20(1):17. PubMed ID: 36949442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Metabolic Effects of Three Different Treatment Combinations with Retrospective Real-life Data in People Living with HIV.
    Simsek A; Karabay O; Guclu E; Toptan H
    Curr HIV Res; 2023; 21(5):314-322. PubMed ID: 37990894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
    Angione SA; Cherian SM; Özdener AE
    J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
    Imaz A; Podzamczer D
    Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up.
    Calza L; Borderi M; Colangeli V; Borioni A; Coladonato S; Granozzi B; Viale P
    Infect Dis (Lond); 2020 Apr; 52(4):249-256. PubMed ID: 31876437
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen.
    Rizzardini G; Gori A; Miralles C; Olalla J; Molina JM; Raffi F; Kumar P; Antinori A; Ramgopal M; Stellbrink HJ; Das M; Chu H; Ram R; Garner W; Shao Y; Chuck SK; Piontkowsky D; Haubrich RH
    AIDS; 2019 Aug; 33(10):1583-1593. PubMed ID: 31305329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
    N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
    M Llibre J; Raffi F; Moyle G; Behrens G; Bouee S; Reilly G; Borg P; Piontkowsky D; Rogatto F
    PLoS One; 2016; 11(5):e0155406. PubMed ID: 27196332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.